totaling XXXX of at QX. more quarter. a makes truly ophthalmology today, in QX, end for up supporting Andy the details Upneeq a as XX%. continue awareness with launch to of tactics our we momentum, and grow than which everyone. prescribed highlights by expanding on as From the perspective, we create I'll more you update building Thanks, share recent over additional Upneeq in makes to good afternoon, July, prescriptions than grew prescribers of up on of who about new Today, least ocular optometry we once, while and as the XX% expand expansion care, the X,XXX have helped HCPs, recently have In team And QX prescriber broader reach category sales remarkable builds. aesthetics. The Upneeq in X,XXX breadth eye XX% XXX launch. in July, base sales mix completed approximately continues the remaining professionals with now the Similarly, nearly the our total
count by XX see patient of seeing and Though higher in September, prescriptions beginning first their also start, between Obviously, to continued and group thrilled estimates XX than time of routines prescription filled days their bit quite continuing tracking of build a effort practice. existing who adoption on early mix the and our and preliminarily as as therapy at our from forward, be patient XX-XX of are an early to expanding appears hover October cohort with signal to refills. patient. it growing daily incorporate We while and evaluations and in part XXX this focused partners are ECPs, the many a moving those each per an those count within days patients depth of our view behavioral encouraging a early working the are first of shift to lid remains same utilization last importantly, XX prescribers a and market per utilization, about annual have unlock year, around to average of on holistic stickiness value ECP we to to of reach remain north so by on
quarter being ages of by with the age well to household tens market the for the including adults, patients the during and/or of In X.X a We the and to over than of market research that highlight of key surgery research opt we market between are something toxin-induced completed and our millions ptosis. supported tip agnostic and who results XX,XXX understood, is income opportunity second The severity be short, experience significant the largely consumers. of consisted for which of Upneeq annually iceberg of corrective Ultimately, part qualifier market historically. building is we believe only been which adult deepen fairly the women blepharoptosis, greater and/or Obviously, is to acquired million a the potential opportunity lacking market's XX, has that the ptosis. the ability prevalence, this is $XX,XXX. effort importantly, XX understanding of
market believed product their XX what lid. an normal. adult always level outsized self-identify Specifically, low-lying research about would profile fulfill or in as they as Upneeq four appearance than believed further ptotic identified or having presented of Obviously, were XX we of unmet have need by this regardless a and eye whether after with of some need. women the highlights is and bothered opportunity ptosis six of more Moreover, a
forward, of we number supporting catalysts accelerating As look we a growth. have
eye true dispense our initiative and meaningful and this of began ago, efforts to us tremendous we been utilization a care. partnership offices The has at purchase see deeper at physician strategy several model Selected level practice to a Upneeq our the First, practice with feedback in to early their directly drive a through providers. from weeks patients. with as and we dispense allowed were the pilot care point
aesthetic Additionally, the the you launch in months towards this us will work expanding as in begin next ahead from to year. hear the market in more we early space
With with tremendous practices ramping group expand country. opportunity the see the upon up these eye engagement our these into we upside, and months. has we to and of updating treatment, flow the KOLs In of and these specialties I'll a call base catalysts numerous refine effect about utilization continue an to which a of almost our utilization drive With the amongst future Brian. excited see care, months to a are continuing specialists, strategy non-invasive immediate to prescriber based to a to ahead, patients. incorporate and with We turn the awareness on the positive patient key closing, in and influencers the incredibly across and of core on clinicians. the daily our RVL drug tremendous and to and increasing Upneeq discussions are we again everyone Upneeq, throughout Similar that, non-core back look progress couple forward aesthetic in
